Nov 17 (Reuters) – Sellas Life Sciences said on Tuesday its experimental vaccine helped patients with a type of blood cancer live longer in a late-stage trial.
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow.
Patients who received GPS lived a median of 24 months, compared to 14.7 months for those given the best available treatment, Sellas said.
The company plans to talk to the US Food and Drug Administration about seeking approval for the vaccine. Its shares were halted in premarket trading.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)

